Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 1 shows the distribution of Grade 3 and 4 non-hematologic adverse events reported in this study.
Authors: MacLean S. Hall, John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew S. Beatty, Jamie Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris Wiener, Benjamin Schachner, Alberto J. Martinez, Allison D. Richards, Carolyn J. Rich, Marjorie Colón Colón, Michael J. Schell, Jamie K. Teer, Nikhil I. Khushalani, Jeffrey S. Weber, James J. Mulé, Vernon K. Sondak, Shari Pilon-Thomas, Amod A. Sarnaik
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416672227
Cites:
Cited by:
Related to: